Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, 862-0973, Japan.
Pharmaceutical Industries Research Division, Pharmacognosy Department, National Research Centre, 33 El Bohouth St. (Former El Tahrir St.), Dokki, P.O. 12622, Giza, Egypt.
J Nat Med. 2022 Jun;76(3):575-583. doi: 10.1007/s11418-022-01622-5. Epub 2022 Apr 10.
Osteoporosis is a disease that affects the quality of life of elderly people. The balance between bone formation mediated by osteoblasts and bone resorption by osteoclasts is important to maintain the normal bone condition. Therefore, the promotion of osteoblast differentiation and the suppression of osteoclastogenesis are effective strategies for osteoporosis treatment. Marine organisms are a promising source of biologically active and structurally diverse secondary metabolites, and have been providing drug leads for the treatment of numerous diseases. We describe the marine-derived secondary metabolites that can inhibit receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclastogenesis and promote osteoblast differentiation.
骨质疏松症是一种影响老年人生活质量的疾病。成骨细胞介导的骨形成和破骨细胞介导的骨吸收之间的平衡对于维持正常的骨骼状态很重要。因此,促进成骨细胞分化和抑制破骨细胞生成是治疗骨质疏松症的有效策略。海洋生物是生物活性和结构多样的次生代谢产物的有前途的来源,已经为治疗许多疾病提供了药物先导化合物。我们描述了可以抑制核因子-κB 受体激活剂配体(RANKL)诱导的破骨细胞生成并促进成骨细胞分化的海洋来源的次生代谢产物。